Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484335 | 0.88 | HDAC1 (0.75) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4488293 | 0.88 | HDAC6 (0.75) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4492176 | 0.88 | HDAC1 (0.75) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4485209 | 0.88 | HDAC6 (0.70) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4483037 | 0.88 | HDAC6 (0.58) | HDAC6HDAC1HDAC2HDAC8DYRK1A | |
| SCHEMBL4488951 | 0.88 | HDAC6 (0.64) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4493050 | 0.87 | GSK3B (0.72) | HDAC6HDAC1HDAC2HDAC8GSK3B | |
| SCHEMBL4491569 | 0.87 | HDAC1 (0.80) | HDAC6HDAC1HDAC2HDAC8GSK3B | |
| SCHEMBL4486394 | 0.85 | HDAC6 (0.66) | HDAC6HDAC1HDAC2HDAC8FGFR4 | |
| SCHEMBL4497932 | 0.85 | HDAC6 (0.66) | HDAC6HDAC1HDAC2HDAC8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | HDAC6 3478/4885HDAC1 3369/4885HDAC2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.